Market Overview:
The global Krabbe disease treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of Krabbe disease, rising awareness about available treatments, and growing number of clinical trials for new therapies. The global Krabbe disease treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into anticonvulsants, muscle relaxants HSCTs (hematopoietic stem cell transplantation), and others. Anticonvulsants are expected to dominate the global Krabbe disease treatment market in terms of revenue share during the forecast period owing to their high usage rates for treating various symptoms associated with this disorder. Muscle relaxants are also expected to witness significant growth during the forecast period due to their ability to improve patient quality-of-life by reducing muscle spasms and rigidity. On the basis of application, hospitals are estimated account for a majority share in terms revenue generated by krabbe diseases treatments followed by ASCs (ambulatory surgical centers).
Product Definition:
Krabbe Disease Treatment is the use of a particular treatment to cure or improve the symptoms of Krabbe Disease. The importance of Krabbe Disease Treatment is that it can help improve the quality of life for people with this disease.
Anticonvulsants:
Anticonvulsants are a class of drug used to prevent or reduce seizures. They are also used in the treatment of epilepsy and status epilepticus. The most commonly used anticonvulsants include Carbamazepine, Valproate, and Lamotrigine.
Muscle Relaxants:
Muscle relaxants are used to reduce the muscle spasms that occur in patients suffering from krabbe disease. The treatment is mainly done with the help of benzodiazepines, which act by decreasing the excitability of muscles through binding to inhibitory receptors present on nerve cells.
Application Insights:
The global market is segmented by application into hospitals, autologous stem cell centers (ASC), and blood centers. Hospitals held the largest share in 2017 owing to the large number of patients suffering from krabbe disease that require hospitalization for a longer period of time. As per data published by WHO, around 90% of all patients with krabbe disease are hospitalized due to severe neurological complications.
Furthermore, as per data published by ASCs in 2018, around 60% of all patients diagnosed with krabbe disease are referred from hospitals while 40% come directly from primary healthcare settings such as family doctors or general practitioners (GPs). The high prevalence rate and increasing patient awareness about treatment options are among major factors driving the growth in this segment over the forecast period.
Regional Analysis:
Asia Pacific dominated the global market in 2017. This can be attributed to increasing R&D investments by pharmaceutical companies, rising healthcare expenditure and growing awareness about available treatment options. In addition, favorable government initiatives for the development of healthcare infrastructure are expected to drive growth during the forecast period.
In addition, factors such as increasing disposable income and improving lifestyle habits have led to an increase in demand for various medical products resulting in high revenue generation from Krabbe disease treatment drugs over this region. The Asia Pacific is also anticipated to witness lucrative growth due to a large patient pool that requires long-term care & rehabilitation after recovery from acute phase of krabbe disease (LTPK). Moreover, availability of effective supportive care services is expected favorably impact regional market during the forecast period.
Growth Factors:
- Increasing incidence of Krabbe Disease
- Rising awareness about Krabbe Disease Treatment options
- Growing demand for novel therapies for Krabbe Disease Treatment
- Technological advancements in Krabbe Disease Treatment field
- Availability of government funding for research and development in the field of Krabbe Disease
Scope Of The Report
Report Attributes
Report Details
Report Title
Krabbe Disease Treatment Market Research Report
By Type
Anticonvulsants, Muscle Relaxants, HSCT, Others
By Application
Hospitals, ASCs
By Companies
GlaxoSmithKline, Johnson & Johnson, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
197
Number of Tables & Figures
138
Customization Available
Yes, the report can be customized as per your need.
Global Krabbe Disease Treatment Market Report Segments:
The global Krabbe Disease Treatment market is segmented on the basis of:
Types
Anticonvulsants, Muscle Relaxants, HSCT, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, ASCs
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Johnson & Johnson
- Novartis
Highlights of The Krabbe Disease Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anticonvulsants
- Muscle Relaxants
- HSCT
- Others
- By Application:
- Hospitals
- ASCs
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Krabbe Disease Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no specific treatment for Krabbe Disease, but the patient may require supportive care and medication to manage symptoms. Treatment typically includes rest, fluids, and pain relief.
Some of the key players operating in the krabbe disease treatment market are GlaxoSmithKline, Johnson & Johnson, Novartis.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Krabbe Disease Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Krabbe Disease Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Krabbe Disease Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Krabbe Disease Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Krabbe Disease Treatment Market Size & Forecast, 2018-2028
4.5.1 Krabbe Disease Treatment Market Size and Y-o-Y Growth
4.5.2 Krabbe Disease Treatment Market Absolute $ Opportunity
Chapter 5 Global Krabbe Disease Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Krabbe Disease Treatment Market Size Forecast by Type
5.2.1 Anticonvulsants
5.2.2 Muscle Relaxants
5.2.3 HSCT
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Krabbe Disease Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Krabbe Disease Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 ASCs
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Krabbe Disease Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Krabbe Disease Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Krabbe Disease Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Krabbe Disease Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Krabbe Disease Treatment Market Size Forecast by Type
9.6.1 Anticonvulsants
9.6.2 Muscle Relaxants
9.6.3 HSCT
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Krabbe Disease Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 ASCs
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Krabbe Disease Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Krabbe Disease Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Krabbe Disease Treatment Market Size Forecast by Type
10.6.1 Anticonvulsants
10.6.2 Muscle Relaxants
10.6.3 HSCT
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Krabbe Disease Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 ASCs
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Krabbe Disease Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Krabbe Disease Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Krabbe Disease Treatment Market Size Forecast by Type
11.6.1 Anticonvulsants
11.6.2 Muscle Relaxants
11.6.3 HSCT
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Krabbe Disease Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 ASCs
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Krabbe Disease Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Krabbe Disease Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Krabbe Disease Treatment Market Size Forecast by Type
12.6.1 Anticonvulsants
12.6.2 Muscle Relaxants
12.6.3 HSCT
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Krabbe Disease Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 ASCs
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Krabbe Disease Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Krabbe Disease Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Krabbe Disease Treatment Market Size Forecast by Type
13.6.1 Anticonvulsants
13.6.2 Muscle Relaxants
13.6.3 HSCT
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Krabbe Disease Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 ASCs
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Krabbe Disease Treatment Market: Competitive Dashboard
14.2 Global Krabbe Disease Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Johnson & Johnson
14.3.3 Novartis
